Skip to main content

Roche Holding AG (RHHBF)

OTC Markets (US) Healthcare Drug Manufacturers - GeneralView data quality →
53.9Fair

ValueMarkers Composite Index

Top 50%#22,365 of 44,714
Slightly Undervalued

13% below intrinsic value ($601)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.65
Low Risk
Altman
5.12
Safe
DCF Value
$601
Undervalued
ROIC
20.4%
Strong
P/E
19.6
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Roche Holding AG (RHHBF) — VMCI valuation read

Roche Holding AG sits at VMCI 54/100, with the Healthcare sector median at 50. That 4-point spread is the first thing to note on RHHBF: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on RHHBF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on RHHBF: RHHBF trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 0.3x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

RHHBF rose 2.0% over the trailing 7 days, with a -4.8% read on a 30-day basis.

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.

CEO: Thomas Schinecker103,249 employeesCHwww.roche.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in RHHBF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.